Additional file 7 of Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Supplementary appendix 7. Number of patients experiencing adverse events and adverse reactions who received any dose of selumetinib

Institutions

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.28629965
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additional file 7 of Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Figshare
PI3K/AKT/mTOR signaling in cancer
article

Additional file 7 of Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

article en

Abstract

Supplementary appendix 7. Number of patients experiencing adverse events and adverse reactions who received any dose of selumetinib

Figshare
Sheffield Teaching Hospitals NHS Foundation Trust (GB), The Christie NHS Foundation Trust (GB), Chelsea and Westminster Hospital (GB), University Hospitals Sussex NHS Foundation Trust (GB), University of Birmingham (GB), University of Sheffield (GB), University of Edinburgh (GB)
Good health and well-being
Openalex Percentile: Top 53%
PI3K/AKT/mTOR signaling in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.